Rhinofacial conidiobolomycosis: Clinical and microbiological characterisation and shift in the management of a rare disease.

Itraconazole and potassium iodide are reasonable first-line options for the treatment of conidiobolomycosis. Good clinical response to KI and comparatively lower MIC of co-trimoxazole are promising. Further studies are required for developing clinical breakpoints that can predict therapeutic outcomes.